Year: 2021
Type: article
Abstract: Polycystic ovarian syndrome (PCOS) is a heterogeneous endocrine disorder with the underline indication of ovarian cysts, anovulation, and endocrine variation affecting the women. According to the World Health Organization (WHO) estimation revealed over 116 million women (3.4%) are affected by PCOS worldwide. The predisposing risk factors include genetics, neuroendocrine, lifestyle/environment, obesity that contributes to the development of PCOS. The pathophysiological aspect of PCOS mainly focuses on hormonal dysfunction, insulin resistance, and hyperandrogenism leading to impaired folliculogenesis which arise the risk for associated comorbidities like endometrial cancer, type II diabetes. This review highlights a brief overview of risk and pathophysiological treatment with drugs acting on anovulation, infertility plus clinical symptoms of PCOS.
Source: Endocrine and Metabolic Science
Authors: Jeshica Bulsara, Priyanshi Patel, Arun Soni, Sanjeev Acharya
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,500
OpenAlex ID: W3128341602
